Russia may postpone restrictions on procurement of imported drugs
The Russian government may revise its earlier announced plans to impose restrictions on procurement of imported drugs to public hospitals and other state needs, with the aim of providing support to domestic producers.
Earlier this year, the Russian government said it is considering imposing a ban on the participation of foreign drug producers in the tendering for public procurement of drugs in Russia, in the event that at least two similar drugs, produced by local manufacturers are present on the market (The Pharma Letter January 10).
The announcement of these plans has already caused massive protest both from foreign producers, operating in the Russian market as well as patients. According to analysts’ estimates, the restrictions may affect up to 500 well-known essential drugs, including antibiotics, anti-cancer drugs, drugs for the treatment of other pathologies, etc.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze